References
  1. E. Tolosa, A. Garrido, S.W. Scholz, W. Poewe, Challenges in the diagnosis of Parkinson’s disease, Lancet Neurol. 20 (2021) 385–397. https://doi.org/10.1016/S1474-4422(21)00030-2.
  2. E.R. Dorsey, A. Elbaz, E. Nichols, N. Abbasi, F. Abd-Allah, A. Abdelalim, J.C. Adsuar, M.G. Ansha, C. Brayne, J.-Y.J. Choi, D. Collado-Mateo, N. Dahodwala, H.P. Do, D. Edessa, M. Endres, S.-M. Fereshtehnejad, K.J. Foreman, F.G. Gankpe, R. Gupta, S. Hamidi, G.J. Hankey, S.I. Hay, M.I. Hegazy, D.T. Hibstu, A. Kasaeian, Y. Khader, I. Khalil, Y.-H. Khang, Y.J. Kim, Y. Kokubo, G. Logroscino, J. Massano, N. Mohamed Ibrahim, M.A. Mohammed, A. Mohammadi, M. Moradi-Lakeh, M. Naghavi, B.T. Nguyen, Y.L. Nirayo, F.A. Ogbo, M.O. Owolabi, D.M. Pereira, M.J. Postma, M. Qorbani, M.A. Rahman, K.T. Roba, H. Safari, S. Safiri, M. Satpathy, M. Sawhney, A. Shafieesabet, M.S. Shiferaw, M. Smith, C.E.I. Szoeke, R. Tabarés-Seisdedos, N.T. Truong, K.N. Ukwaja, N. Venketasubramanian, S. Villafaina, K. gideyweldegwergs, R. Westerman, T. Wijeratne, A.S. Winkler, B.T. Xuan, N. Yonemoto, V.L. Feigin, T. Vos, C.J.L. Murray, Global, regional, and national burden of Parkinson’s disease, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016, The Lancet Neurology. 17 (2018) 939–953. https://doi.org/10.1016/S1474-4422(18)30295-3.
  3. Z. Wassouf, J.M. Schulze‐Hentrich, Alpha‐synuclein at the nexus of genes and environment: the impact of environmental enrichment and stress on brain health and disease, J. Neurochem. 150 (2019) 591–604. https://doi.org/10.1111/jnc.14787.
  4. S.R. Subramaniam, M.-F. Chesselet, Mitochondrial dysfunction and oxidative stress in Parkinson’s disease, Progress in Neurobiology. 106–107 (2013) 17–32. https://doi.org/10.1016/j.pneurobio.2013.04.004.
  5. K. Chatterjee, A. Roy, R. Banerjee, S. Choudhury, B. Mondal, S. Halder, P. Basu, S. Shubham, S. Dey, H. Kumar, Inflammasome and α-synuclein in Parkinson’s disease: A cross-sectional study, Journal of Neuroimmunology. 338 (2020) 577089. https://doi.org/10.1016/j.jneuroim.2019.577089.
  6. Pignolo, S. Mastrilli, C. Davì, V. Arnao, P. Aridon, F.A. dos Santos Mendes, C. Gagliardo, M. D’Amelio, Vitamin D and Parkinson’s Disease, Nutrients. 14 (2022) 1220. https://doi.org/10.3390/nu14061220.
  7. Z. Zhou, R. Zhou, Z. Zhang, K. Li, The Association Between Vitamin D Status, Vitamin D Supplementation, Sunlight Exposure, and Parkinson’s Disease: A Systematic Review and Meta-Analysis, Med SciMonit. 25 (2019) 666–674. https://doi.org/10.12659/MSM.912840.
  8. S.-M. Jeon, E.-A. Shin, Exploring vitamin D metabolism and function in cancer, Exp Mol Med. 50 (2018) 1–14. https://doi.org/10.1038/s12276-018-0038-9.
  9. P.N. MacDonald, Transcriptional activation through the vitamin D receptor in osteoblasts, Front Biosci. 3 (1998) d821-833. https://doi.org/10.2741/A325.
  10. D. Gezen-Ak, M. Alaylıoğlu, G. Genç, A. Gündüz, E. Candaş, B. Bilgiç, İ.L. Atasoy, H. Apaydın, G. Kızıltan, H. Gürvit, H. Hanağası, S. Ertan, S. Yılmazer, E. Dursun, GC and VDR SNPs and Vitamin D Levels in Parkinson’s Disease: The Relevance to Clinical Features, Neuromol Med. 19 (2017) 24–40. https://doi.org/10.1007/s12017-016-8415-9.
  11. P.T. Gomme, J. Bertolini, Therapeutic potential of vitamin D-binding protein, Trends in Biotechnology. 22 (2004) 340–345. https://doi.org/10.1016/j.tibtech.2004.05.001.
  12. J.R. Delanghe, R. Speeckaert, M.M. Speeckaert, Behind the scenes of vitamin D binding protein: More than vitamin D binding, Best Practice & Research Clinical Endocrinology & Metabolism. 29 (2015) 773–786. https://doi.org/10.1016/j.beem.2015.06.006.
  13. S. Malik, L. Fu, D.J. Juras, M. Karmali, B.Y.L. Wong, A. Gozdzik, D.E.C. Cole, Common variants of the vitamin D binding protein gene and adverse health outcomes, Critical Reviews in Clinical Laboratory Sciences. 50 (2013) 1–22. https://doi.org/10.3109/10408363.2012.750262.
  14. Anjum, S.S. Jaffery, M. Fayyaz, Z. Samoo, S. Anjum, The Role of Vitamin D in Brain Health: A Mini Literature Review, Cureus. (2018). https://doi.org/10.7759/cureus.2960.
  15. G.A. Laughlin, D. Kritz-Silverstein, J. Bergstrom, E.T. Reas, S.K. Jassal, E. Barrett-Connor, L.K. McEvoy, Vitamin D Insufficiency and Cognitive Function Trajectories in Older Adults: The Rancho Bernardo Study, JAD. 58 (2017) 871–883. https://doi.org/10.3233/JAD-161295.
  16. M. Barichella, F. Garrì, S. Caronni, C. Bolliri, L. Zocchi, M.C. Macchione, V. Ferri, D. Calandrella, G. Pezzoli, Vitamin D Status and Parkinson’s Disease, Brain Sciences. 12 (2022) 790. https://doi.org/10.3390/brainsci12060790.
  17. N. Kumar, R. Gupta, H. Kumar, S. Mehta, R. Rajan, D. Kumar, R.M. Kandadai, S. Desai, P. Wadia, P. Basu, B. Mondal, Sanchita, A. Rawat, S.S. Meka, B. Mishal, L.K. Prashanth, A.K. Srivastava, V. Goyal, Impact of home confinement during COVID-19 pandemic on Parkinson’s disease, Parkinsonism & Related Disorders. 80 (2020) 32–34. https://doi.org/10.1016/j.parkreldis.2020.09.003.
  18. E.R. Dorsey, B.R. Bloem, The Parkinson Pandemic—A Call to Action, JAMA Neurol. 75 (2018) 9. https://doi.org/10.1001/jamaneurol.2017.3299.
  19. P. Aparna, S. Muthathal, B. Nongkynrih, S. Gupta, Vitamin D deficiency in India, J Family Med Prim Care. 7 (2018) 324. https://doi.org/10.4103/jfmpc.jfmpc_78_18.
  20. S. Das, G. Das, B. Ghosh, J. Ray, A. Biswas, Movement disorders: Indian scenario: A clinico-genetic review, Neurol India. 61 (2013) 457. https://doi.org/10.4103/0028-3886.121908.
  21. J. Piñero, J. Saüch, F. Sanz, L.I. Furlong, The DisGeNETcytoscape app: Exploring and visualizing disease genomics data, Computational and Structural Biotechnology Journal. 19 (2021) 2960–2967. https://doi.org/10.1016/j.csbj.2021.05.015.
  22. P. Shannon, A. Markiel, O. Ozier, N.S. Baliga, J.T. Wang, D. Ramage, N. Amin, B. Schwikowski, T. Ideker, Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks, Genome Res. 13 (2003) 2498–2504. https://doi.org/10.1101/gr.1239303.
  23. V. Landel, D. Stephan, X. Cui, D. Eyles, F. Feron, Differential expression of vitamin D-associated enzymes and receptors in brain cell subtypes, The Journal of Steroid Biochemistry and Molecular Biology. 177 (2018) 129–134. https://doi.org/10.1016/j.jsbmb.2017.09.008.
  24. N. Roy M., Impact of vitamin D on neurocognitive function in dementia, depression, schizophrenia and ADHD, Front Biosci. 26 (2021) 566–611. https://doi.org/10.2741/4908.
  25. P. Koduah, F. Paul, J.-M. Dörr, Vitamin D in the prevention, prediction and treatment of neurodegenerative and neuroinflammatory diseases, EPMA Journal. 8 (2017) 313–325. https://doi.org/10.1007/s13167-017-0120-8.
  26. S.Y. Kang, S. Park, E. Oh, J. Park, J. Youn, J.S. Kim, J.-U. Kim, W. Jang, Vitamin D receptor polymorphisms and Parkinson’s disease in a Korean population: Revisited, Neuroscience Letters. 628 (2016) 230–235. https://doi.org/10.1016/j.neulet.2016.06.041.
  27. W. Hu, L. Wang, B. Chen, X. Wang, Vitamin D receptor rs2228570 polymorphism and Parkinson’s disease risk in a Chinese population, Neuroscience Letters. 717 (2020) 134722. https://doi.org/10.1016/j.neulet.2019.134722.
  28. H. Liu, X. Han, X. Zheng, Y. Li, A. Xie, [Association of vitamin D receptor gene polymorphisms with Parkinson disease], Zhonghua Yi Xue Yi ChuanXueZaZhi. 30 (2013) 13–16. https://doi.org/10.3760/cma.j.issn.1003-9406.2013.01.004.
  29. R. Mohammadzadeh, R. Pazhouhesh, Association of VDR FokI and ApaI genetic polymorphisms with parkinson’s disease risk in South Western Iranian population, Acta Med Int. 3 (2016) 111. https://doi.org/10.5530/ami.2016.1.24.
  30. M.S. Petersen, S. Bech, D.H. Christiansen, A.V. Schmedes, J. Halling, The role of vitamin D levels and vitamin D receptor polymorphism on Parkinson’s disease in the Faroe Islands, Neuroscience Letters. 561 (2014) 74–79. https://doi.org/10.1016/j.neulet.2013.12.053.
  31. C.-H. Lin, K.-H. Chen, M.-L. Chen, H.-I. Lin, R.-M. Wu, Vitamin D receptor genetic variants and Parkinson’s disease in a Taiwanese population, Neurobiology of Aging. 35 (2014) 1212.e11-1212.e13. https://doi.org/10.1016/j.neurobiolaging.2013.10.094.
  32. M. Suzuki, M. Yoshioka, M. Hashimoto, M. Murakami, K. Kawasaki, M. Noya, D. Takahashi, M. Urashima, 25-hydroxyvitamin D, vitamin D receptor gene polymorphisms, and severity of Parkinson’s disease: Vitamin D and Parkinson’s Disease, Mov. Disord. 27 (2012) 264–271. https://doi.org/10.1002/mds.24016.
  33. R. Török, N. Török, L. Szalardy, I. Plangar, Z. Szolnoki, F. Somogyvari, L. Vecsei, P. Klivenyi, Association of vitamin D receptor gene polymorphisms and Parkinson’s disease in Hungarians, Neuroscience Letters. 551 (2013) 70–74. https://doi.org/10.1016/j.neulet.2013.07.014.
  34. M. Alaylıoğlu, E. Dursun, G. Genç, B. Şengül, B. Bilgiç, A. Gündüz, H. Apaydın, G. Kızıltan, H. Gürvit, H. Hanağası, Ö. ÖztopÇakmak, S. Ertan, S. Yılmazer, D. Gezen-Ak, Genetic variants of vitamin D metabolism-related DHCR7/NADSYN1 locus and CYP2R1 gene are associated with clinical features of Parkinson’s disease, International Journal of Neuroscience. 132 (2022) 439–449. https://doi.org/10.1080/00207454.2020.1820502.
  35. P. Troncoso-Escudero, A. Parra, M. Nassif, R.L. Vidal, Outside in: Unraveling the Role of Neuroinflammation in the Progression of Parkinson’s Disease, Front. Neurol. 9 (2018) 860. https://doi.org/10.3389/fneur.2018.00860.
  36. K. Saijo, B. Winner, C.T. Carson, J.G. Collier, L. Boyer, M.G. Rosenfeld, F.H. Gage, C.K. Glass, A Nurr1/CoREST Pathway in Microglia and Astrocytes Protects Dopaminergic Neurons from Inflammation-Induced Death, Cell. 137 (2009) 47–59. https://doi.org/10.1016/j.cell.2009.01.038.
  37. R. Calvello, A. Cianciulli, G. Nicolardi, F. De Nuccio, L. Giannotti, R. Salvatore, C. Porro, T. Trotta, M.A. Panaro, D.D. Lofrumento, Vitamin D Treatment Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in an Animal Model of Parkinson’s Disease, Shifting M1 to M2 Microglia Responses, J NeuroimmunePharmacol. 12 (2017) 327–339. https://doi.org/10.1007/s11481-016-9720-7.
  38. M. Mangin, R. Sinha, K. Fincher, Inflammation and vitamin D: the infection connection, Inflamm. Res. 63 (2014) 803–819. https://doi.org/10.1007/s00011-014-0755-z.
  39. G. Bivona, L. Agnello, C. Bellia, G. Iacolino, C. Scazzone, B. Lo Sasso, M. Ciaccio, Non-Skeletal Activities of Vitamin D: From Physiology to Brain Pathology, Medicina. 55 (2019) 341. https://doi.org/10.3390/medicina55070341.
  40. C. Marogianni, M. Sokratous, E. Dardiotis, G.M. Hadjigeorgiou, D. Bogdanos, G. Xiromerisiou, Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson’s Disease, IJMS. 21 (2020) 8421. https://doi.org/10.3390/ijms21228421.
  41. M.E. Fullard, J.E. Duda, A Review of the Relationship Between Vitamin D and Parkinson Disease Symptoms, Front. Neurol. 11 (2020) 454. https://doi.org/10.3389/fneur.2020.00454.
  42. M. Fronczek, J.K. Strzelczyk, K. Biernacki, S. Salatino, T. Osadnik, Z. Ostrowska, New Variants of the Cytochrome P450 2R1 (CYP2R1) Gene in Individuals with Severe Vitamin D-Activating Enzyme 25(OH)D Deficiency, Biomolecules. 11 (2021) 1867. https://doi.org/10.3390/biom11121867.
  43. C.-H. Lin, C.-C. Chen, H.-L. Chiang, J.-M. Liou, C.-M. Chang, T.-P. Lu, E.Y. Chuang, Y.-C. Tai, C. Cheng, H.-Y. Lin, M.-S. Wu, Altered gut microbiota and inflammatory cytokine responses in patients with Parkinson’s disease, J Neuroinflammation. 16 (2019) 129. https://doi.org/10.1186/s12974-019-1528-y.
  44. H. Braak, U. Rüb, W.P. Gai, K. Del Tredici, Idiopathic Parkinson’s disease: possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen, Journal of Neural Transmission. 110 (2003) 517–536. https://doi.org/10.1007/s00702-002-0808-2.
  45. C. Follmer, Viral Infection-Induced Gut Dysbiosis, Neuroinflammation, and α-Synuclein Aggregation: Updates and Perspectives on COVID-19 and Neurodegenerative Disorders, ACS Chem. Neurosci. 11 (2020) 4012–4016. https://doi.org/10.1021/acschemneuro.0c00671.
  46. M. Pajares, A. I. Rojo, G. Manda, L. Boscá, A. Cuadrado, Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications, Cells. 9 (2020) 1687. https://doi.org/10.3390/cells9071687.
  47. Giulietti, E. van Etten, L. Overbergh, K. Stoffels, R. Bouillon, C. Mathieu, Monocytes from type 2 diabetic patients have a pro-inflammatory profile. 1,25-Dihydroxyvitamin D(3) works as anti-inflammatory, Diabetes Res ClinPract. 77 (2007) 47–57. https://doi.org/10.1016/j.diabres.2006.10.007.
  48. X. Chen, W. Cao, Y. Zhuang, S. Chen, X. Li, Integrative analysis of potential biomarkers and immune cell infiltration in Parkinson’s disease, Brain Research Bulletin. 177 (2021) 53–63. https://doi.org/10.1016/j.brainresbull.2021.09.010.
  49. K.W. Hofmann, A.F.S. Schuh, J. Saute, R. Townsend, D. Fricke, R. Leke, D.O. Souza, L.V. Portela, M.L.F. Chaves, C.R.M. Rieder, Interleukin-6 Serum Levels in Patients with Parkinson’s Disease, Neurochem Res. 34 (2009) 1401–1404. https://doi.org/10.1007/s11064-009-9921-z.
  50. D.-J. Choi, J.-K. Kwon, E.-H. Joe, A Parkinson’s disease gene, DJ-1, regulates astrogliosis through STAT3, Neuroscience Letters. 685 (2018) 144–149. https://doi.org/10.1016/j.neulet.2018.08.025.
  51. M.L. Block, L. Zecca, J.-S. Hong, Microglia-mediated neurotoxicity: uncovering the molecular mechanisms, Nat Rev Neurosci. 8 (2007) 57–69. https://doi.org/10.1038/nrn2038.
  52. P. Przanowski, M. Dabrowski, A. Ellert-Miklaszewska, M. Kloss, J. Mieczkowski, B. Kaza, A. Ronowicz, F. Hu, A. Piotrowski, H. Kettenmann, J. Komorowski, B. Kaminska, The signal transducers Stat1 and Stat3 and their novel target Jmjd3 drive the expression of inflammatory genes in microglia, J Mol Med (Berl). 92 (2014) 239–254. https://doi.org/10.1007/s00109-013-1090-5.
  53. S. Tanaka, A. Ishii, H. Ohtaki, S. Shioda, T. Yoshida, S. Numazawa, Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice, J Neuroinflammation. 10 (2013) 143. https://doi.org/10.1186/1742-2094-10-143.
  54. Y. Xu, D.J. Baylink, C.-S. Chen, M.E. Reeves, J. Xiao, C. Lacy, E. Lau, H. Cao, The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19, J Transl Med. 18 (2020) 322. https://doi.org/10.1186/s12967-020-02488-5.
  55. F. Català-Moll, A. G. Ferreté-Bonastre, G. Godoy-Tena, O. Morante-Palacios, L. Ciudad, L.Barberà, F. Fondelli, E.MMartínez-Cáceres, J. Rodríguez-Ubreva, J., Li, T., &E Ballestar, (2022). Vitamin D receptor, STAT3, and TET2 cooperate to establish tolerogenesis. Cell reports. 38 (2022). https://doi.org/10.1016/j.celrep.2021.110244
  56. V.K. Raker, M.P. Domogalla, K. Steinbrink, Tolerogenic Dendritic Cells for Regulatory T Cell Induction in Man, Front. Immunol. 6 (2015). https://doi.org/10.3389/fimmu.2015.00569.
  57. A.N. Rcom‐H’cheo‐Gauthier, A.C.B. Meedeniya, D.L. Pountney, Calcipotriol inhibits α‐synuclein aggregation in SH ‐ SY 5Y neuroblastoma cells by a Calbindin‐D28k‐dependent mechanism, J. Neurochem. 141 (2017) 263–274. https://doi.org/10.1111/jnc.13971.